Published in Drug Week, October 17th, 2003
The research will be carried out by Antigen Express, Generex's subsidiary focused on the development of novel immunomedicines.
The grant supports the design, synthesis, and testing of potent Ii-Key/melanoma peptides for possible subsequent clinical studies. The laboratory experiments will be performed in test tubes with lymphocytes from melanoma patients. The most reactive Ii-Key/melanoma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.